"Canagliflozin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
Descriptor ID |
D000068896
|
MeSH Number(s) |
D02.886.778.075 D03.383.903.075 D09.408.348.113
|
Concept/Terms |
Canagliflozin- Canagliflozin
- Canagliflozin Hemihydrate
- Hemihydrate, Canagliflozin
Canagliflozin, Anhydrous- Canagliflozin, Anhydrous
- Anhydrous Canagliflozin
- 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene - T777973
|
Below are MeSH descriptors whose meaning is more general than "Canagliflozin".
Below are MeSH descriptors whose meaning is more specific than "Canagliflozin".
This graph shows the total number of publications written about "Canagliflozin" by people in this website by year, and whether "Canagliflozin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Below are the most recent publications written about "Canagliflozin" by people in Profiles.
-
Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, in-vitro, in silico, and in-vivo study. Drug Deliv. 2023 Dec; 30(1):2241665.
-
The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia/Reperfusion Injury in Rats. Int J Mol Sci. 2021 Jul 21; 22(15).
-
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis. Clin J Am Soc Nephrol. 2021 03 08; 16(3):384-395.
-
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program. Am J Kidney Dis. 2021 01; 77(1):23-34.e1.
-
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 06 13; 380(24):2295-2306.
-
Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)". Circulation. 2018 02 27; 137(9):986-987.